Kelly Lawrence W & Associates’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-200
Closed -$20.3K 128
2025
Q4
$20.3K Hold
200
﹤0.01% 120
2025
Q3
$10.9K Hold
200
﹤0.01% 146
2025
Q2
$10.6K Sell
200
-960
-83% -$48.8K ﹤0.01% 144
2025
Q1
$50.2K Hold
1,160
0.01% 115
2024
Q4
$65.2K Hold
1,160
0.02% 111
2024
Q3
$79K Hold
1,160
0.02% 109
2024
Q2
$49K Hold
1,160
0.01% 121
2024
Q1
$80.1K Hold
1,160
0.02% 103
2023
Q4
$85.8K Hold
1,160
0.02% 102
2023
Q3
$79.1K Hold
1,160
0.02% 102
2023
Q2
$109K Hold
1,160
0.03% 89
2023
Q1
$78.7K Hold
1,160
0.02% 95
2022
Q4
$57.4K Hold
1,160
0.02% 100
2022
Q3
$38K Hold
1,160
0.01% 123
2022
Q2
$46K Hold
1,160
0.01% 123
2022
Q1
$81K Hold
1,160
0.02% 101
2021
Q4
$90K Buy
1,160
+60
+5% +$5.29K 0.02% 104
2021
Q3
$105K Buy
1,100
+300
+38% +$31.7K 0.02% 94
2021
Q2
$99K Buy
800
+200
+33% +$23.9K 0.02% 103
2021
Q1
$79K Buy
600
+200
+50% +$27.4K 0.02% 101
2020
Q4
$53K Hold
400
0.02% 68
2020
Q3
$41K Hold
400
0.01% 95
2020
Q2
$35K Sell
400
-100
-20% -$7.99K 0.01% 92
2020
Q1
$29K Buy
+500
New +$40.6K 0.01% 97

Other funds holding EXAS

Kelly Lawrence W & Associates's EXAS Position: Q1 2026 in Review

Kelly Lawrence W & Associates sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 200 shares — an estimated $20.3K sold.

Kelly Lawrence W & Associates first reported a position in EXAS in Q1 2020 and held it in 24 quarters. The position peaked at $109K in Q2 2023. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Kelly Lawrence W & Associates reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Kelly Lawrence W & Associates sold 200 Exact Sciences shares in Q1 2026, an estimated $20.3K.
  • Kelly Lawrence W & Associates first reported a position in Exact Sciences in Q1 2020 and held it in 24 quarters.
  • Kelly Lawrence W & Associates's Exact Sciences position peaked at $109K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Kelly Lawrence W & Associates's 13F filing for Q1 2026, filed 15 May 2026.